Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice.

Osei-Hyiaman D, Liu J, Zhou L, Godlewski G, Harvey-White J, Jeong WI, Bátkai S, Marsicano G, Lutz B, Buettner C, Kunos G.

J Clin Invest. 2008 Sep;118(9):3160-9. doi: 10.1172/JCI34827.

2.

Understanding metabolic homeostasis and imbalance: what is the role of the endocannabinoid system?

Kunos G.

Am J Med. 2007 Sep;120(9 Suppl 1):S18-24; discussion S24. Review.

PMID:
17720356
3.

The role of the endocannabinoid system in the control of energy homeostasis.

Osei-Hyiaman D, Harvey-White J, Bátkai S, Kunos G.

Int J Obes (Lond). 2006 Apr;30 Suppl 1:S33-8. Review.

PMID:
16570103
4.

Endocannabinoids in liver disease.

Tam J, Liu J, Mukhopadhyay B, Cinar R, Godlewski G, Kunos G.

Hepatology. 2011 Jan;53(1):346-55. doi: 10.1002/hep.24077. Review.

5.

The hepatic cannabinoid 1 receptor as a modulator of hepatic energy state and food intake.

Cooper ME, Regnell SE.

Br J Clin Pharmacol. 2014 Jan;77(1):21-30. doi: 10.1111/bcp.12102. Review.

6.

The role of muscle insulin resistance in the pathogenesis of atherogenic dyslipidemia and nonalcoholic fatty liver disease associated with the metabolic syndrome.

Jornayvaz FR, Samuel VT, Shulman GI.

Annu Rev Nutr. 2010 Aug 21;30:273-90. doi: 10.1146/annurev.nutr.012809.104726. Review.

7.

New insights on the role of the endocannabinoid system in the regulation of energy balance.

Gatta-Cherifi B, Cota D.

Int J Obes (Lond). 2016 Feb;40(2):210-9. doi: 10.1038/ijo.2015.179. Epub 2015 Sep 16. Review.

PMID:
26374449
8.

The case for peripheral CB₁ receptor blockade in the treatment of visceral obesity and its cardiometabolic complications.

Kunos G, Tam J.

Br J Pharmacol. 2011 Aug;163(7):1423-31. doi: 10.1111/j.1476-5381.2011.01352.x. Review.

9.

Lipodystrophy: metabolic insights from a rare disorder.

Huang-Doran I, Sleigh A, Rochford JJ, O'Rahilly S, Savage DB.

J Endocrinol. 2010 Dec;207(3):245-55. doi: 10.1677/JOE-10-0272. Epub 2010 Sep 24. Review.

10.

The role of endocannabinoids system in fatty liver disease and therapeutic potentials.

Alswat KA.

Saudi J Gastroenterol. 2013 Jul-Aug;19(4):144-51. doi: 10.4103/1319-3767.114505. Review.

11.

Re-visiting the Endocannabinoid System and Its Therapeutic Potential in Obesity and Associated Diseases.

Richey JM, Woolcott O.

Curr Diab Rep. 2017 Sep 14;17(10):99. doi: 10.1007/s11892-017-0924-x. Review.

PMID:
28913816
12.

New horizons on the role of cannabinoid CB1 receptors in palatable food intake, obesity and related dysmetabolism.

Cristino L, Palomba L, Di Marzo V.

Int J Obes Suppl. 2014 Jul;4(Suppl 1):S26-30. doi: 10.1038/ijosup.2014.8. Epub 2014 Jul 8. Review.

13.

Genetic determinants of cardiometabolic risk: a proposed model for phenotype association and interaction.

Blackett PR, Sanghera DK.

J Clin Lipidol. 2013 Jan-Feb;7(1):65-81. doi: 10.1016/j.jacl.2012.04.079. Epub 2012 Apr 22. Review.

Supplemental Content

Support Center